Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Arvinas, Inc.NASDAQ: ARVN

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -369.2%

Net margin was -369.2% in Q1 FY2026, down 413.1 pp from a year earlier. On a trailing-twelve-month basis it was -247.5%, down 236.6 pp year over year. Over 3 fiscal years it widened by 184.2 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 10 analysts of 3.2% for the fiscal year ending Dec 2026, up from -30.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-369.2%+340.2 pp QoQ
Last fiscal yearDec 2025
-30.8%+44.7 pp YoY
LTMMar 2026
-247.5%-236.6 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-413.1 pp+232.9 pp+646.1 pp
1 year+44.7 pp+33.9 pp-10.8 pp
3 years+184.2 pp-295.2 pp-479.5 pp
5 years-17.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-30.8%
Year-over-year change
+44.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 net margin of -247.5% is the 2nd highest of the 6 companies compared; the peer median is -285.4%.
  • Its year-over-year change of -236.6 pp is the 5th highest of 6, against a peer median of +75.4 pp.
  • Over three fiscal years its change of +184.2 pp compares with a peer median of +136.1 pp.
ARVN Competitors Peer median
Net Margin for ARVN and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202642.0% +334.5 pp+152.0 pp
ARVNArvinas, Inc.LTM Mar 2026-247.5% -236.6 pp+184.2 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-266.9% +75.4 pp+325.9 pp
KYMRKymera Therapeutics, Inc.LTM Jun 2026-285.4% +330.6 pp-463.8 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-297.8% -38.2 pp+120.1 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-302.7% -306.5 pp—
Peer median (excluding ARVN) -285.4%+75.4 pp+136.1 pp

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue53.6M131.4M78.5M263.4M262.6M
Cost of Revenue00005.2M
Gross Profit53.6M131.4M78.5M263.4M257.4M
Gross Margin100.0%100.0%100.0%100.0%98.0%
Research & Development180.4M315M379.7M348.2M282.9M
Selling, General & Admin61.6M79.6M100.3M165.4M89.4M
Operating Expenses242M394.6M480M513.6M372.3M
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
EBITDA(184.9M)(253.4M)(359.7M)(191.7M)(75.3M)
EBITDA Margin-345.0%-192.8%-458.2%-72.8%-28.7%
Operating Income(188.4M)(263.2M)(401.5M)(250.2M)(114.9M)
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Income1.8M12M38.8M54.8M22M
Interest Expense100K0000
Other Income / Expenses(2.6M)1.6M35.1M51.9M34.4M
Income Before Tax(191M)(261.6M)(366.4M)(198.3M)(80.5M)
Pre-Tax Margin-356.3%-199.1%-466.8%-75.3%-30.7%
Income Tax Expense020.9M900K600K300K
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Basic)(3.82)(5.31)(6.62)(2.77)(1.28)
EPS (Diluted)(3.82)(5.31)(6.62)(2.77)(1.28)
Weighted Avg Shares50M53.2M55.5M71.9M64.9M
Weighted Avg Shares (Diluted)50M53.2M55.5M71.9M64.9M

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.